Beigene (6160.HK): Range-bound fluctuations, cautious and repeated capital, the game in the pharmaceutical sector becomes complex before new regulations

On February 3rd, BeiGene experienced significant fluctuations throughout the day, opening high and then pulling back. Although funds were somewhat active in the short term, supporting a slight rebound, the overall trend showed weakness. Currently, the pharmaceutical sector is relatively mild, with some long-term funds testing the waters as the market rebounds. The main operators displayed clear hesitation and repetition, with the day's rhythm primarily characterized by strong fluctuations. Recently, the market has focused on news such as "new contracts in the CXO business," which has activated short-term funds related to pharmaceuticals. However, despite increased trading volume, the main funds are still primarily engaged in range trading, leading to intensified overall bullish-bearish divergence and a strong wait-and-see atmosphere. The MACD daily signal has shown some phase repair, but the pressure from the unblocking area above the stock price and long-term resistance remains heavy, with no clear signs of sustained upward movement from the main operators. On the news front, there are currently no major disturbances in the pharmaceutical sector, and the rotation of themes and active funds has revealed structural opportunities. The intraday performance showed a high opening and pullback, with multiple tests of the 20-day line, where right-side funds dominated the intraday game. However, the volume cooperation is limited, constraining the rebound space, and the signals from large orders are scattered. Overall, a new round of regulatory details for the pharmaceutical industry is about to be released, becoming a key focus for the market and significantly impacting the sector's trend. The risk exposure cannot be ignored; if negative news arises or if the main operators significantly reduce their holdings, the pressure will intensify. It is recommended to continue monitoring policy dynamics and changes in hotspots within the pharmaceutical sector, dynamically managing positions to cope with uncertainties